Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19.

ABSTRACT:

SUBMITTER: Chew KW 

PROVIDER: S-EPMC8722620 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature